Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study (Q41904942)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 February 2011

Language	Label	Description	Also known as
English	Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study	scientific article published on 25 February 2011

Statements

scholarly article

1 reference

Europe PubMed Central

13 October 2017

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study (English)

1 reference

Europe PubMed Central

13 October 2017

zoledronic acid

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

1

object named as

Karim Fizazi

1 reference

Europe PubMed Central

13 October 2017

author name string

Michael Carducci

2

1 reference

Europe PubMed Central

13 October 2017

Matthew Smith

3

1 reference

Europe PubMed Central

13 October 2017

Ronaldo Damião

4

1 reference

Europe PubMed Central

13 October 2017

Janet Brown

5

1 reference

Europe PubMed Central

13 October 2017

Lawrence Karsh

6

1 reference

Europe PubMed Central

13 October 2017

Piotr Milecki

7

1 reference

Europe PubMed Central

13 October 2017

Neal Shore

8

1 reference

Europe PubMed Central

13 October 2017

Michael Rader

9

1 reference

Europe PubMed Central

13 October 2017

Huei Wang

10

1 reference

Europe PubMed Central

13 October 2017

Qi Jiang

11

1 reference

Europe PubMed Central

13 October 2017

Sylvia Tadros

12

1 reference

Europe PubMed Central

13 October 2017

Roger Dansey

13

1 reference

Europe PubMed Central

13 October 2017

Carsten Goessl

14

1 reference

Europe PubMed Central

13 October 2017

language of work or name

0 references

publication date

25 February 2011

1 reference

Europe PubMed Central

13 October 2017

1 reference

Europe PubMed Central

13 October 2017

377

1 reference

Europe PubMed Central

13 October 2017

813-822

1 reference

Europe PubMed Central

13 October 2017

9768

1 reference

Europe PubMed Central

13 October 2017

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Treatment and prevention of bone complications from prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Role of targeted therapy in the treatment of advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Estimates of cancer incidence and mortality in Europe in 2008.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Histopathological assessment of prostate cancer bone osteoblastic metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

New research findings on zoledronic acid: survival, pain, and anti-tumour effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Significance and impact of bisphosphonate-induced acute phase responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Osteoclast differentiation and activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Bone markers in the management of patients with skeletal metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

18 August 2018

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

18 August 2018

Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

18 August 2018

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

18 August 2018

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

18 August 2018

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

18 August 2018

Economic burden of metastatic bone disease in the U.S.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962344-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Some fundamental issues with non-inferiority testing in active controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962344-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cox's Regression Model for Counting Processes: A Large Sample Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962344-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962344-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962344-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone

1 reference

https://pubmed.ncbi.nlm.nih.gov/21353695

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/S0140-6736(10)62344-6

1 reference

Europe PubMed Central

13 October 2017

1 reference

Europe PubMed Central

13 October 2017

1 reference

Europe PubMed Central

13 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41904942&oldid=1929667671"